Description

Cimacef (Cefuroxime) 0.75 g Vial for Intravenous Administration

Composition

Active Ingredient: Cefuroxime

Inactive ingredients may include sodium carbonate, sodium chloride, and sterile water for injection.

Mechanism of Action

Cimacef exerts its pharmacological action by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Pharmacological Properties

Cefuroxime, a second-generation cephalosporin antibiotic, demonstrates broad-spectrum activity against various bacteria.

Indications for Use

Cimacef is indicated for the treatment of infections caused by susceptible strains of bacteria, including lower respiratory tract infections, skin and skin structure infections, and urinary tract infections.

Contraindications

Cimacef is contraindicated in patients with a known allergy to cephalosporins.

Side Effects

Common side effects of Cimacef may include gastrointestinal disturbances, allergic reactions, and superinfection.

Usage Instructions

The usual adult dose of Cimacef is 750 mg to 1.5 grams every 8 hours, administered intravenously over a period of 30 minutes to 1 hour. Dosage adjustments are recommended for patients with renal impairment.

Benefits Compared to Analogues

Compared to other cephalosporins, Cimacef exhibits enhanced stability against beta-lactamases, making it a valuable option in the treatment of infections caused by multidrug-resistant pathogens.

Suitable Patient Groups

Cimacef is suitable for adult patients, including the elderly, but caution is advised in patients with known renal impairment.

Storage and Shelf Life

Cimacef should be stored at the recommended temperature and protected from light. Check the product packaging for specific storage instructions. The shelf life of Cimacef is typically indicated on the packaging.

Packaging Description

Cimacef (Cefuroxime) 0.75 g vial for intravenous administration is typically packaged in single-dose vials for convenient use in healthcare settings.

Clinical Evidence and Proven Effectiveness

Clinical studies have demonstrated the efficacy of cefuroxime in treating various infections, such as community-acquired pneumonia and skin infections. Research published in the International Journal of Antimicrobial Agents has highlighted the effectiveness of cefuroxime in combating multidrug-resistant pathogens.